38
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

A Randomized Controlled Trial of the Clinical Utility of Genotypic Resistance Testing in Patients with Limited Prior Exposure to Antiretroviral Drugs

Pages 183-186 | Published online: 14 Jan 2015

REFERENCES

  • Torre D, Tambini R. Antiretroviral drug resistance testing in patients with HIV-1 infection: a meta-analysis study. HIV Clin Trials. 2002;3(1):1–8.
  • Dunn DT, Gibb DM, Babiker AG, Darbyshire JH, Green H. A methodological critique of RCTs of HIV drug resistance testing. Controlled Clin Trials. 2003;24(3S):194S.
  • Evaluation of Resistance Assays (ERA) Trial Investigators. A randomised controlled trial of the value of phenotypic testing in addition to genotypic testing for HIV drug resis-tance. J Acquir Immune Defic Syndr. 2005;38:553–559.
  • Mazzotta F, Caputo SL, Torti C, et al. Real versus virtual phenotype to guide treatment in heavily pretreated pa-tients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) Trial. J AIDS. 2003;32:268–280.
  • Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommen-dations of an International AIDS Society-USA panel. JAMA. 2000;283:2417–2426.
  • The EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommenda-tions for the European setting. AIDS. 200115: 309–320.
  • Janosky JE, Hughes JR, Lilford RJ, Halpern SD, Karlawish JHT, Berlin JA. The ethics of underpowered clinical trials. JAMA. 2002;288:2118–2119.
  • Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 1999;353:2195–2199.
  • Meynard JL, Vray M, Morand-Joubert L, et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS. 2002,16:727–736.
  • Cohen C, Hunt S, Sension M, et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS. 2002;16:579–588

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.